Cramer Won't Buy UnitedHealth Under Probe, But Says Some Think 'The Worst Is Over'

Jim Cramer expressed skepticism toward AGNC Investment Corp. following its Q2 earnings of $0.38/share, which missed the $0.41 consensus, citing its lack of growth. Conversely, UnitedHealth Group (UNH) shares surged 8.6% as the company reaffirmed its 2025 adjusted EPS target of at least $16.00/share, slightly below analyst consensus, and clarified the dilutive impact of its Amedisys acquisition. This reaffirmation, despite an ongoing investigation and the acquisition's anticipated dilution, was seemingly viewed by the market as a positive sign of clarity for UNH's outlook.

Analysis

The market is demonstrating a clear divergence in its treatment of AGNC Investment Corp. (AGNC) and UnitedHealth Group (UNH), prioritizing guidance clarity over minor shortfalls. AGNC is viewed unfavorably, aligning with Jim Cramer's critique of it as a non-growth vehicle, a sentiment underscored by its second-quarter earnings miss of $0.38 per share versus a $0.41 analyst consensus. The stock's negligible 0.1% rise reflects this negative outlook. In stark contrast, UnitedHealth shares surged 8.6% despite several headwinds. The company reaffirmed its 2025 adjusted EPS target of at least $16.00, which is below the analyst consensus of $16.24-$16.30, and acknowledged that its Amedisys acquisition would be dilutive. This strong positive market reaction suggests investors are valuing the certainty of a reaffirmed earnings floor, viewing it as a signal that the negative impacts of an ongoing investigation and acquisition costs are now quantified and manageable.

Key Decisions for Investors

• Investors should scrutinize AGNC Investment's lack of growth catalysts, as its recent earnings miss and flat stock performance validate concerns that it does not fit a growth-oriented strategy.
• For UnitedHealth, the significant 8.6% stock gain upon reaffirming guidance indicates the market is prioritizing forward-looking certainty and may believe the risks from its investigation and acquisition are now priced in.
• Consider that the market heavily rewarded UnitedHealth for providing a clear earnings floor, suggesting that in the current volatile climate, demonstrable stability and transparent guidance can outweigh minor misses against consensus or existing operational headwinds.